D-Sumitomo Looks To Fill BBI608 Colorectal Cancer Hole
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo has now formally halted patient registration in a Phase III monotherapy trial with BBI608 for advanced colorectal cancer, and is looking to other projects to fill the gap.